GSK
GSK’s Arzerra conditionally approved in Europe
April 20, 2010Research and Development, Sales and Marketing Arzerra, GSK, leukaemia
GlaxoSmithKline’s orphan cancer treatment Arzerra has been given conditional marketing authorisation in the European Union. Arzerra (ofatumumab) can be used …
Reprieve for GSK workers as NY plant closure is cancelled
April 13, 2010Manufacturing and Production GSK
The jobs of up to 210 workers at a GlaxoSmithKline plant in New York, USA, have been saved after the …
GSK agrees generic deal on Malarone
April 13, 2010Sales and Marketing GSK, depression, generics
Generic versions of two GlaxoSmithKline products have received the green light for launch in the US. Mylan has been given …
UK recoups cost from unused H1N1 vaccine
April 7, 2010Sales and Marketing GSK, NHS, h1n1
The UK government has agreed a deal with GlaxoSmithKine on surplus supplies of its H1N1 vaccine Pandemrix. The Department of …
GSK and Crucell to develop malaria vaccine
April 7, 2010Sales and Marketing Crucell, GSK, malaria
GlaxoSmithKline Biologicals and Dutch vaccines company Crucell are to develop a ‘second generation’ malaria vaccine candidate. Malaria causes 900,000 deaths …
Virus contamination found in GSK’s Rotarix
March 23, 2010Business Services, Manufacturing and Production, Sales and Marketing Contamination, GSK, Vaccine, manufacturing compliance
The European Medicines Agency has demanded more information “as a matter of urgency” from GlaxoSmithKline over a virus in its …
GSK plans obesity documentary
January 29, 2010Medical Communications Alli, GSK, obesity
Obesity is about to get the Hollywood treatment with GlaxoSmithKline Consumer Healthcare funding a documentary by Oscar-winning director Barry Levinson. …
In brief: European Medicines Agency news
January 26, 2010Research and Development, Sales and Marketing Arepanrix, Arzerra, EMEA, GSK, Tysabri
GlaxoSmithKline’s influenza vaccine Arepanrix has been granted conditional marketing authorisation in Europe under an emergency fast-track procedure.It is the fourth …
GSK’s Andrew Witty appointed president of EFPIA
January 5, 2010Research and Development, Sales and Marketing Andrew Witty, EFPIA, GSK, appointment, research and development, sales and marketing
GlaxoSmithKline chief executive Andrew Witty has been appointed president of EFPIA.He previously served as vice-president of the European industry association for two years and takes …
Pharma mergers and acquisitions in 2009
December 22, 2009Research and Development, Sales and Marketing Abbott, GSK, J&J, JJ, M&A, MA, Novartis, Pfizer, Wyeth, generics, industry, merger, year in review
This year saw two ‘mega mergers’ in the sector, the acquisition of Wyeth by Pfizer and the reverse takeover of …
GSK discloses US healthcare professional payments
December 15, 2009Medical Communications GSK, doctors, industry reputation, payments
GlaxoSmithKline has disclosed some of the fees it has paid to US healthcare professionals for speaking and consulting services.The list …
GSK to invest in UK manufacturing thanks to ‘patent box’ concept
December 11, 2009Manufacturing and Production GSK, biopharmaceutical
GlaxoSmithKline has welcomed plans for a new UK government initiative the ‘patent box’ aimed at stimulating investment in the UK. …
Digital Pharma: A Year in Digital (2/5)
December 10, 2009Medical Communications 2009, GSK, digi, digital pharma, year in review
Favourite use of digital (pharma)Creative Lynx & Jansen-Cilag’s Concerta XL Tablet PC campaignFavourite use of digital (non-pharma)BBC iPlayerFavourite social media …
GSK licences smoking vaccine candidate
November 30, 2009Research and Development GSK, Nabi, smoking, vaccines
GlaxoSmithKline Biologicals has signed a licensing agreement for a nicotine vaccine candidate currently in the first of two phase III …
Latest content
ESTEVE CDMO adds $17.5m to Illinois expansion
Brenntag and dsm-firmenich expand biopharma vitamin partnership
